Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Telix Pharmaceuticals ( (AU:TLX) ) has shared an announcement.
Telix Pharmaceuticals has provided an update on its ProstACT Global Phase 3 study involving TLX591, a prostate cancer therapy candidate targeting metastatic castration-resistant prostate cancer (mCRPC). The company has successfully completed Part 1 of the study and has now initiated Part 2 across several countries, following positive safety and clinical results. This study marks a significant milestone in the development of TLX591, as it combines a PSMA-targeted radio antibody-drug conjugate with existing Standard of Care treatments, promising a unique therapeutic alternative with fewer adverse effects. Expansion into additional global jurisdictions, including Europe, is underway, enhancing Telix’s industry positioning and reinforcing its commitment to advancing innovative oncology solutions.
The most recent analyst rating on (AU:TLX) stock is a Hold with a A$17.00 price target. To see the full list of analyst forecasts on Telix Pharmaceuticals stock, see the AU:TLX Stock Forecast page.
More about Telix Pharmaceuticals
Telix Pharmaceuticals is a biopharmaceutical company headquartered in Melbourne, Australia, specializing in the development and commercialization of radiopharmaceuticals for diagnostic and therapeutic use in oncology and rare diseases. With a presence in multiple countries, the company has a pipeline of clinical and commercial-stage products aimed at addressing unmet medical needs, including its approved PSMA-PET imaging agent Illuccix® and ongoing trials like TLX591 for prostate cancer therapy.
Average Trading Volume: 1,931,099
Technical Sentiment Signal: Sell
Current Market Cap: A$4.25B
Learn more about TLX stock on TipRanks’ Stock Analysis page.